- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
~ New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.S.-based workflow. ~
~ Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions.~
Appointment underscores Champions’ focus on leveraging clinically relevant data to power next-generation oncology R&D
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025, Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025.
Positive start to FY 2026 with steady revenue, data growth and new leadership
Total annual revenue growth of 14%
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025.
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
